Verve Therapeutics, Inc. 

Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to

Are you a current or former employee of the company?*YesNo


+Additional Purchases


+Additional Sales

If you prefer, you may submit your transaction information or comments/questions in the box below:

There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.

We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at, or by email at

If you choose to take no action, you can remain an absent class member.

Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.

The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

Portnoy Law Firm
Lesley F. Portnoy, Esq.,
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067

The investigation is centered on determining whether the Company released false and/or misleading statements or neglected to disclose important information that could impact investors. Verve has become the subject of a MarketWatch report that was published on November 13, 2023. According to the report, the Company’s shares experienced a significant decline of 40% during premarket trading on Monday. This decline followed the release of early-stage clinical trial data on the Company’s experimental gene-editing treatment for high cholesterol, which was disclosed by the Company on the preceding Sunday. The report goes on to state that the results from Verve’s trials “failed to meet the high expectations that were built up leading into the data release,” as noted by analysts from Leerink Partners in a commentary provided on Monday.